EUVIMEDEUVIMED entdecken
Crossref

Outcomes of Scar-Related Ventricular Tachycardia Ablation With Percutaneous Left Ventricular Assist Device Support

Iwanari Kawamura, Jacob S Koruth, Shigeki Kusa, Jin Iwasawa, Jeff Lam, Betsy Ellsworth, Keita Watanabe, Moritz Nies, Joshua Lampert, Abhishek Maan, Daniel R Musikantow, Mohit K Turagam und 5 weitere

JACC: Clinical Electrophysiology · 2025

DOI: 10.1016/j.jacep.2025.07.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2025. Verfasst von Iwanari Kawamura und 16 weiteren Autor:innen. Beteiligte Einrichtung: Helmsley Electrophysiology Center, Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Department of Cardiova…. Hauptthemen laut MEDLINE: Tachycardia, Ventricular, Heart-Assist Devices, Catheter Ablation, Cicatrix. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Percutaneous left ventricular assist devices (pLVADs) are often used in critically ill patients undergoing scar-related ventricular tachycardia (VT) ablation. However, there are no randomized controlled trials evaluating their benefits. OBJECTIVES: The goal of this study was to compare outcomes between pLVAD- and non-pLVAD-supported VT ablation using a propensity score matching analysis. METHODS: This retrospective analysis comprised 481 scar-related VT patients who underwent catheter ablation (175 pLVAD and 306 non-pLVAD). A 1:1 propensity score matching was conducted to balance baseline characteristics for comparison of procedural and long-term outcomes. RESULTS: A propensity score analysis generated 115 matched pairs in each group. Baseline characteristics of the matched cohorts were comparable (mean left ventricular ejection fraction 27%, 40% NYHA functional class ≥III, and 36% electrical storm). Compared with the non-pLVAD, more patients in the pLVAD group had at least 1 VT termination during ablation. Despite including a higher use of advanced ablation strategies and a longer procedure time, the pLVAD group had a postprocedural VT inducibility similar to that of the non-pLVAD group. The incidence of periprocedural major complications was higher among pLVAD patients (29.6% vs 13.9%; P = 0.004), largely driven by vascular complications requiring intervention and periprocedural heart failure. During a median follow-up of 326 days, Kaplan-Meier curves showed no statistically significant differences in composite outcome (hospitalization for VT or worsening heart failure requiring hospitalization, LVAD implantation, orthotopic heart transplantation, and all-cause mortality), and VT recurrence. CONCLUSIONS: The use of pLVADs during VT ablation is associated with longer procedures and higher procedural complications without any benefit in acute or long-term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tachycardia, VentricularHeart-Assist DevicesCatheter AblationCicatrixHumansMaleFemaleRetrospective StudiesMiddle AgedTreatment OutcomeAgedPropensity Score

Stichwörter der Autor:innen

Impellacatheter ablationhemodynamic supportpercutaneous mechanical circulatory supportprophylacticventricular tachycardia

Autor:innen und Institutionen

  • Helmsley Electrophysiology Center, Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Department of Cardiovascular Medicine, Institute of Science Tokyo, Tokyo, Japan.
  • Helmsley Electrophysiology Center, Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Helmsley Electrophysiology Center, Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Cardiovascular Center, Tsuchiura Kyodo Hospital, Ibaraki, Japan.
  • Helmsley Electrophysiology Center, Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Department of Cardiology, Heart Rhythm Center, International University of Health and Welfar…
  • Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Helmsley Electrophysiology Center, Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: srinivas.dukkipati@mountsinai.org.

Zitieren

APA

Kawamura, I., Koruth, J. S., Kusa, S., Iwasawa, J., Lam, J., Ellsworth, B., Watanabe, K., Nies, M., Lampert, J., Maan, A., Musikantow, D. R., Turagam, M. K., Moss, N., Whang, W., Miller, M. A., Reddy, V. Y., & Dukkipati, S. (2025). Outcomes of Scar-Related Ventricular Tachycardia Ablation With Percutaneous Left Ventricular Assist Device Support. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2025.07.016

Vancouver

Kawamura I, Koruth JS, Kusa S, Iwasawa J, Lam J, Ellsworth B, et al. Outcomes of Scar-Related Ventricular Tachycardia Ablation With Percutaneous Left Ventricular Assist Device Support. JACC: Clinical Electrophysiology. 2025. doi:10.1016/j.jacep.2025.07.016

BibTeX
@article{Kawamura2025,
  author = {Kawamura, Iwanari and Koruth, Jacob S and Kusa, Shigeki and Iwasawa, Jin and Lam, Jeff and Ellsworth, Betsy and Watanabe, Keita and Nies, Moritz and Lampert, Joshua and Maan, Abhishek and Musikantow, Daniel R and Turagam, Mohit K and Moss, Noah and Whang, William and Miller, Marc A and Reddy, Vivek Y and Dukkipati, Srinivas},
  title = {Outcomes of Scar-Related Ventricular Tachycardia Ablation With Percutaneous Left Ventricular Assist Device Support},
  journal = {JACC: Clinical Electrophysiology},
  year = {2025},
  doi = {10.1016/j.jacep.2025.07.016}
}
Kostenlos starten →